Overview

Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.